Greyson International, Inc. Introduces Two New Trilexon® Products with Successful Clinical Study Results
Showing Significant Pore Size Reductions Greater than 50 Percent
BOCA RATON, Fla.—September 20, 2010 — Greyson International, Inc. (GYSN.PK) announced today that it is introducing two new Trilexon® products: Trilexon® Facial Cleanser and Trilexon® Pore Tightening Facial Toner. These products underwent independent clinical testing performed by world-renowned physician Dr. Peter Pugliese; both products performed exceptionally well in all parameters. The study found that, together, the Trilexon® Facial Cleanser and Trilexon® Pore Tightening Facial Toner comprise a superior cleansing and restorative system for the skin.
“It is with great enthusiasm that we introduce these two new unique products in the Trilexon® collection,” said Greyson International CEO Harvey Tauman. “The fact that the clinical studies performed on the Trilexon® Facial Cleanser and Trilexon® Pore Tightening Facial Toner show a reduction in the size of pores by significantly greater than 50 percent is a testimony to the true efficacy of these products. With the addition of our cleanser and toner, we are proud to bring a full collection of Trilexon® products to the major global health and beauty companies that we are currently meeting with to discuss the licensing of Trilexon® for their most well-known brands.”
Tauman added, “We look forward to discussing our two new products, as well as other significant business developments, in an upcoming conference call. A press release announcing a date and time for this call will be forthcoming.”
The clinical study for the Trilexon® Facial Cleanser found that it is a very mild but highly effective cleanser and safe to use. The product does not remove the natural moisturizing component of the skin, but is capable of removing excess lipids, which are the cause of skin oiliness. The cleanser maintains a 5-5.5 pH, allowing it to maintain physiological activity. It also produces a smooth texture on the skin because of the product’s added anti-inflammatory and anti-oxidant botanicals, which also provide additional protection from environmental toxins and a soothing effect to the skin.
The clinical study for the Trilexon® Pore Tightening Facial Toner was conducted on skin that was cleansed with Trilexon® Facial Cleanser. The study on the Trilexon® Pore Tightening Facial Toner found that it is capable of reducing pore size significantly greater than 50 percent. The toner maintains a 5-5.5 pH, allowing it to maintain physiological activity. It acts to control oiliness by helping to reduce excess sebum production, and assists in maintaining the natural moisturizing factor of the skin.
The independent clinical studies on the Trilexon® Facial Cleanser and Trilexon® Pore Tightening Facial Toner were performed by Dr. Peter Pugliese, a world-renowned physician who has spent over 25 years studying and specializing in aging mechanisms of human skin. Dr. Pugliese holds several patents, has published hundreds of articles and has lectured on every continent. He was awarded the Maison De Navarre Award for his contributions to cosmetic science. Dr. Pugliese has authored the textbook series Physiology of the Skin, which is a standard esthetic student reference. His latest textbook, Advanced Professional Skin Care, Medical Edition, replaced other teaching materials and has grown in use on a global level.
The Trilexon® Facial Cleanser and Trilexon® Pore Tightening Facial Toner are currently in the packaging stage, and are expected to be ready for purchase by the holiday season.
These two new products join Greyson’s three existing Trilexon® products: Revitalizing Eye Crème with Trilexon® is a breakthrough product specifically designed to treat the sensitive eye area. Restorative Night Crème with Trilexon® goes to work overnight during the nighttime hours, repairing and restoring skin. Fast-Acting Line Erasure with Trilexon® is a revolutionary product that targets and works to eliminate lines and wrinkles.
Trilexon® is a new delivery system designed by Greyson that helps to improve the effectiveness of topical applications by precisely delivering key ingredients to the appropriate areas through “messengers”. Revitalizing Eye Crème with Trilexon®, Restorative Night Crème with Trilexon® and Fast-Acting Line Erasure with Trilexon® each contain specific and effective skincare messengers that are embedded in a fine, invisible, water insoluble film, which is spread over the entire skin being treated and is released slowly to the skin all day and night long. They are not removed by skin perspiration. They are only removed when the skin is washed with a gentle cleanser in the morning or night. Each product also contains a skincare messenger that keeps rebuilding and protecting the skin’s moisture holding ability, so the skin continually stays soft and supple, fresh and beautiful.
Trilexon® has received trademark approval and is patent pending. All Greyson products are manufactured in the U.S. The Company does not test its products on animals.
About Greyson International, Inc.
Greyson International, Inc. is a research, development and marketing company that markets health and beauty aid products. Greyson has developed a new delivery method, the Trilexon® system, which will improve the effectiveness of virtually every topical application in today’s cosmetic market and every over-the-counter topical drug application. Trilexon® is a registered trademark of Greyson International. For more information, visit www.greysonproducts.com, join the Greyson Facebook group page by visiting www.facebook.com and searching “Greyson Products” or follow Greyson on Twitter at www.twitter.com/greysonproducts.
This release contains information about management’s view of our future expectations, plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from historical results or those indicated by these forward-looking statements as a result of a variety of factors including, but not limited to, risks and uncertainties associated with our financial condition, our ability to sell our products and our ability to compete with competitors. We encourage you to review other factors that may affect our future results on any current or future documents we file periodically with the Securities & Exchange Commission.